Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2014

View Archived Issues

Shionogi updates developments of third quarter of fiscal 2013

Roche reviews recent highlights of fourth quarter 2013

Discovery of a novel IAP antagonist with clinical potential for the treatment of cancer

Swiss group presents novel agents for cancer and other disorders

MacroGenics achieves milestone under agreement with Servier for MGD-006

Janssen Pharmaceutica synthesizes new CCR2 receptor antagonists

Merck & Co. collaborates with Amgen, Incyte and Pfizer to study new anticancer regimens

Second-generation proteasome inhibitors could be repurposed as antivirals

Novo Nordisk returns full rights for IPH-2201 to Innate Pharma

Researchers detail design of MPS1 inhibitor CCT-251455

Researchers report novel method of somatic cell reprogramming into bidirectional pluripotent cells

TG-01 enters phase IIa trial in operable pancreatic cancer

Audentes and Genethon enter agreement to develop gene therapy for X-linked myotubular myopathy

Novartis patents novel complement factor D inhibitors

Scientists at Euclises Pharmaceuticals disclose novel antitumor agents

Infectex acquires exclusive rights to Qurient's tuberculosis drug

Argos Therapeutics presents update on the phase III ADAPT trial evaluating AGS-003

Navidea reports initial results from phase IIb trial of its beta-amyloid imaging agent NAV-4694

Shire decides to discontinue development of Vyvanse capsules for major depressive disorder

ProMetic enters new development agreement with vaccines company

REGiMMUNE initiates phase II trial of RGI-2001 for graft versus host disease

FDA accepts NDA filing for Beleodaq

Trigemina expands phase II study of intranasal oxytocin candidate for chronic migraine

Roche reports development of novel cell penetrating peptides for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...